Neither the theories suggesting that SH leads to an UT nor those suggesting that an UT leads to a SH are satisfactory. We believe that this coexistence may be the congenital Spigelian-cryptorchidism syndrome seen in boys. As in the four cases presented here, elements of this syndrome are defects in the Spigelian fascia and the hernia sac enveloping the testis and an absence of the gubernaculum and the inguinal canal.
PS of 0 (n¼39, 15.18%) or 1 (n¼203, 78.99%). The treatment of apatinib was mainly first-line treatment (n¼103, 40.08%), second-line treatment (n¼64, 24.90%), and adjuvant treatment (n¼42, 16.34%). The starting dose of apatinib was 250mg in 132 patients and 500mg in 125 patients. The treatment regimens were: apatinib combined with chemotherapy drugs (178/257), apatinib monotherapy (64/257), apatinib combined with chemotherapy drugs plus PD-1 antibody drug (8/275), and apatinib combined with PD-1 antibody drug (7/275). Thirty-three patients achieved partial response, 69 patients achieved stable disease, and 26 patients had progressive disease, and no CR was achieved, illustrating an ORR of 25.78% and a DCR of 79.69%. During the treatment, the overall incidence of adverse events was 70.82%. The most common adverse events were hypertension (32.68%), leukopenia (26.46%), hand-foot syndrome (25.29%), neutropenia (20.23%), etc.Conclusions: This real-world research showed current treatment status and provided preliminary evidence for the efficacy and safety of apatinib in the treatment of gastric cancer in China. More data would be analyzed and reported in future.[ChiCTR2000035597]Legal entity responsible for the study: The authors.
Objective: One of the most serious complications of pulmonary hydatid cyst is rupture of it. Postrupture asphyxia, anaphylactic shock, acute respiratory failure and massive hemoptysis may occur. In this study, we aimed to present ruptured pulmonary hydatid cyst cases who were followed up and treated in our clinic. Method: In January January 2012-January 2021, patients between 0-18 years of age who underwent surgery for a ruptured hydatid lung cyst in our clinic were included in the study. Age, sex, complaint, cyst localization and surgical technique were evaluated. Results: In 23 (38%) of the 60 cases of hydatid lung cysts included in the study, rupture was diagnosed. Of the ruptured patients, 12 (52%) were girls and 11 (48%) were boys. The median age was 10.2 (5-17) years. The most common cause of admission was cough and fever. The most common localization was right lobe lung involvement. While capitonage was applied to six (26%) patients during the surgical procedure, 22(74%) patients did not. Lobectomy was performed in only one patient. Conclusion: Rupture is the most feared complication in pulmonary hydatid cyst. Therefore, complications that may occur after rupture of patients should be evaluated in terms of surgery in a short period of time.
Background: Around 5% of EGFR gene alterations in non-small cell lung cancer (NSCLC) involve exon 18. Limited prospective data on the therapeutic actionability of individual exon 18 alterations with specific EGFR tyrosine kinase inhibitors (TKIs) are available to guide clinical decision making for these patients.Methods: We conducted a literature search on PubMed using search terms "exon 18" OR "uncommon" OR "non-common" OR "rare" AND "EGFR" AND "NSCLC" OR "lung" for studies published in English on/before 6 February, 2021, that reported patientlevel outcomes from NSCLC patients with defined exon 18 alterations treated with a single named EGFR TKI, with reported progression free survival (PFS) data. We extracted and analysed demographic and clinical data. abstracts Annals of Oncology Volume 32 -Issue S5 -2021 S979
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.